IV Captisol-enabled Melphalan: Phase II/III started

Ligand began an open-label, U.S. Phase II/III trial to evaluate 100 mg/m 2 IV Captisol-enabled Melphalan for 2 days in 60 patients. The product has Orphan Drug designation as a high-dose conditioning ...